HDL and plasma phospholipids in coronary artery disease.

Kúnz, F; Pechlaner, Christoph; Erhart, Reinhold; Fend, Falko; Mühlberger, V.

doi:10.1161/01.atv.14.7.1146

Cited by 43 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have demonstrated a positive correlation between the PL/C of HDL and the capacity of serum to accept cellular cholesterol (40)(41)(42). Furthermore, it has been suggested that a low PL/C in HDL is associated with an increased risk for ischemic vascular disease (43) and coronary artery disease (44). Our data, therefore, suggest that the HDL particles secreted in the presence of 18L and 37pA might be more efficient in promoting cholesterol efflux from the cells.…”

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells

Dashti

Datta

Manchekar

et al. 2004

Journal of Lipid Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 53%

“…The higher apoA-I/ apoB and PL/C ratios, considered good indicators of negative risk for coronary artery disease (40)(41)(42)(43)(44), and the for- Fig. 4.…”

Section: Discussionmentioning

confidence: 99%

Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells

Dashti

Datta

Manchekar

et al. 2004

Journal of Lipid Research

View full text Add to dashboard Cite

“…PON1 activity is substantially lower in patients with CAD, ACS, CKD, and RA, whereas lipoprotein-associated phospholipase A 2 (LpPLA 2 ) activity is increased in CKD and psoriasis (89,137,160,165,(171)(172)(173)(174)(175). Dysregulating the activity of PON1 and LpPLA 2 in this fashion not only compromises the antioxidative activity of HDL, but also promotes the formation of atherosclerotic plaques.…”

Section: Composition and Role Of Hdl-associated Proteinsmentioning

confidence: 99%

The Changing Face of HDL and the Best Way to Measure It

Karathanasis¹,

Freeman

Gordon

et al. 2017

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND: HDL cholesterol (HDL-C) is a commonly used lipid biomarker for assessing cardiovascular health. While a central focus has been placed on the role of HDL in the reverse cholesterol transport (RCT) process, our appreciation for the other cardioprotective properties of HDL continues to expand with further investigation into the structure and function of HDL and its specific subfractions. The development of novel assays is empowering the research community to assess different aspects of HDL function, which at some point may evolve into new diagnostic tests. CONTENT:This review discusses our current understanding of the formation and maturation of HDL particles via RCT, as well as the newly recognized roles of HDL outside RCT. The antioxidative, antiinflammatory, antiapoptotic, antithrombotic, antiinfective, and vasoprotective effects of HDL are all discussed, as are the related methodologies for assessing these different aspects of HDL function. We elaborate on the importance of protein and lipid composition of HDL in health and disease and highlight potential new diagnostic assays based on these parameters.

show abstract

“…The efflux of cholesterol from cells to serum is correlated with HDL PL content (17,18). Importantly, it has been demonstrated that patients with coronary artery disease have low HDL PL levels (19). Past studies have used in vitro manipulation of HDL composition to probe the relationships between HDL PL and cell cholesterol flux.…”

mentioning

confidence: 99%

In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux

Yancey

Kawashiri

Moore

et al. 2004

Journal of Lipid Research

View full text Add to dashboard Cite

The effects of in vivo modulation of HDL phospholipid (PL) on scavenger receptor class BI (SR-BI)-and ATP binding cassette transporter 1 (ABCA1)-mediated efflux were examined by overexpressing either endothelial lipase (EL) or phosphatidylserine phospholipase (PS-PLA 1 ) in human apolipoprotein A-I (apoA-I) transgenic mice. Overexpression of EL led to large reductions in the serum PL/apoA-I ratio ( ؊ 60%), total cholesterol (TC; ؊ 89%), and HDL cholesterol ( ؊ 91%). Relative to the serum before overexpression of EL, the efflux potential of the serum via SR-BI decreased by 90% and ABCA1-mediated efflux increased by 63%. In contrast to overexpression of EL, overexpression of PS-PLA 1 led to increases in the PL/apoA-I ratio (88%), TC (78%), HDL cholesterol (57%), and HDL size. The efflux potential of the serum increased by 60% via SR-BI and decreased by 57% via ABCA1. There were significant positive correlations between SR-BI-mediated efflux and a number of serum parameters, including PL/apoA-I ratio, PL, TC, free cholesterol (FC), and HDL cholesterol. In striking contrast, the same correlations were seen with ABCA1-mediated efflux, but the relationships were inverse. In summary, in vivo modulation of HDL PL content affects ABCA1-and SR-BI-mediated efflux in a reciprocal manner. These findings indicate that the type of lipase acting on HDL in vivo will determine which FC efflux pathway the HDL serves. Additionally, the extent of lipolysis will determine the efficiency of FC removal via this pathway. HDL cholesterol levels are inversely correlated with the incidence of coronary artery disease (1-4). One mechanism by which HDL is thought to protect against atherosclerosis is by the removal of excess free cholesterol (FC) from peripheral cells and subsequent delivery to the liver for excretion (5-7). There are three known mechanisms by which HDL and/or its apolipoproteins can remove FC from cells. Aqueous diffusion is a relatively inefficient efflux mechanism that occurs with all cell types (8). In recent years, two proteins have been discovered that mediate efficient cholesterol efflux. The scavenger receptor class BI (SR-BI) facilitates the bidirectional flux of FC between cells and HDL (9, 10), and the ATP binding cassette transporter 1 (ABCA1) (11-13) mediates the unidirectional efflux of cellular FC and phospholipid (PL) to lipid-poor apolipoprotein A-I (apoA-I) and other exchangeable apolipoproteins. A number of studies suggest that both mechanisms of efflux may operate in atherosclerotic lesions (14-16).The goal of the present study was to determine the effects of in vivo modulation of HDL PL on both ABCA1-and SR-BI-mediated FC efflux. The importance of studying the role of HDL PL in the flux of FC between cells and HDL is supported by a number of previous observations. The efflux of cholesterol from cells to serum is correlated with HDL PL content (17, 18). Importantly, it has been demonstrated that patients with coronary artery disease have low HDL PL levels (19). Past studies have used in vitro mani...

show abstract

HDL and plasma phospholipids in coronary artery disease.

Cited by 43 publications

References 0 publications

Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells

Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells

The Changing Face of HDL and the Best Way to Measure It

In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux

Contact Info

Product

Resources

About